BIOCAD presents results of clinical trial proving efficacy of netakimab at EULAR 2020

BIOCAD presents results of clinical trial proving efficacy of netakimab in the treatment of psoriatic arthritis at the Annual European Congress of Rheumatology (EULAR 2020). Four abstracts present the results from an international randomized double-blind phase 3 clinical trial (PATERA) which demonstrate netakimab decreases disease activity and reduces skin manifestation of psoriatic arthritis through 24 weeks of therapy.